Targeting the body’s complement system, part of the innate immune response, could be a solution for many diseases, including those of the skin and nervous system. But “inherent problems” with this ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing innovative drugs to treat rare diseases and targeted cancers in ...
ADX-097 is designed to inhibit complement activation, an integral part of the innate immune system, and has potential across ...
Dr. Lal PathLabs (DLPL) has announced the launch of complement testing laboratory, strengthening autoimmune diagnostics. This ...
Anemia caused by the autoimmune disorder cold agglutin disease now has its first approved treatment, a Sanofi drug designed to block a pathway key to the progression of this condition. The FDA’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback